Citius Oncology's (CTOR) "Sell (D-)" Rating Reaffirmed at Weiss Ratings

Key Points

• Citius Oncology's stock maintains a "Sell (D-)" rating from Weiss Ratings, despite upgrades by other analysts to "Buy" and "Hold" ratings.
• The stock price is currently at $1.84, down 2.1% from previous trading, with a notable one-year high of $6.19 and a low of $0.55.
• Over 70% of Citius Oncology's stock is held by institutional investors, indicating strong institutional interest in the company.

Citius Oncology (NASDAQ:CTOR - Get Free Report)'s stock had its "sell (d-)" rating reissued by research analysts at Weiss Ratings in a research report issued to clients and investors on Wednesday,Weiss Ratings reports.

Several other equities research analysts also recently issued reports on CTOR. Citigroup upgraded shares of Citius Oncology from a "hold" rating to a "buy" rating in a research note on Tuesday, September 23rd. Maxim Group raised shares of Citius Oncology from a "hold" rating to a "buy" rating and set a $6.00 target price on the stock in a research report on Tuesday, September 23rd. Finally, Wall Street Zen upgraded shares of Citius Oncology to a "hold" rating in a research report on Saturday, July 26th. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of "Hold" and an average target price of $6.00.

Citius Oncology Stock Down 2.1%

Shares of Citius Oncology stock traded down $0.04 during trading on Wednesday, reaching $1.84. The company's stock had a trading volume of 85,338 shares, compared to its average volume of 202,105. The company has a current ratio of 0.35, a quick ratio of 0.02 and a debt-to-equity ratio of 0.12. The business's fifty day moving average price is $1.88 and its 200-day moving average price is $1.65. Citius Oncology has a one year low of $0.55 and a one year high of $6.19.

Hedge Funds Weigh In On Citius Oncology

A number of institutional investors have recently modified their holdings of CTOR. Bank of America Corp DE grew its stake in shares of Citius Oncology by 5,256.9% during the 2nd quarter. Bank of America Corp DE now owns 8,571 shares of the company's stock worth $37,000 after purchasing an additional 8,411 shares during the period. Arkadios Wealth Advisors acquired a new stake in Citius Oncology in the second quarter valued at approximately $51,000. Citadel Advisors LLC acquired a new stake in shares of Citius Oncology during the fourth quarter worth approximately $26,000. Geode Capital Management LLC lifted its stake in Citius Oncology by 179.0% during the second quarter. Geode Capital Management LLC now owns 57,297 shares of the company's stock worth $249,000 after purchasing an additional 36,758 shares during the last quarter. Finally, Jane Street Group LLC bought a new stake in Citius Oncology in the second quarter valued at $465,000. 70.52% of the stock is owned by institutional investors and hedge funds.

About Citius Oncology

Citius Oncology, Inc is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.